STOCK TITAN
  1. Home
  2. News
  3. PRCT

PROCEPT BioRobotics Corporation - $PRCT STOCK NEWS

Welcome to our dedicated page for PROCEPT BioRobotics Corporation news (Ticker: $PRCT), a resource for investors and traders seeking the latest updates and insights on PROCEPT BioRobotics Corporation stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PROCEPT BioRobotics Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PROCEPT BioRobotics Corporation's position in the market.

News
PROCEPT BioRobotics® Announces Preliminary Fourth Quarter Revenue of $43.3 million to $43.6 million
Rhea-AI Summary
PROCEPT BioRobotics Corporation (PRCT) Reports Strong Revenue Growth in Q4 2023, Expects 81-82% Increase in Fiscal Year 2023 Revenue
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.14%
Tags
none
-
News
Neptune Medical Appoints Dr. Fred Moll as Chairman of the Board
Rhea-AI Summary
Neptune Medical (Ticker: NPTM) appoints Dr. Fred Moll, a renowned figure in the medical technology industry, as Chairman of the Board. Dr. Moll, known as the father of medical robotics, brings extensive experience from his roles at Sonder Capital, Intuitive Surgical, and Auris Health. His appointment signifies Neptune Medical's commitment to advancing healthcare technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
management
-
News
PROCEPT BioRobotics to Present at the 35ᵗʰ Annual Piper Sandler Healthcare Conference in New York City
Rhea-AI Summary
PRCT - PROCEPT BioRobotics to Present at 35th Annual Piper Sandler Healthcare Conference in New York City
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.02%
Tags
conferences
News
PROCEPT BioRobotics® Reports Third Quarter 2023 Financial Results and Increases 2023 Revenue Guidance
Rhea-AI Summary
PROCEPT BioRobotics reports unaudited financial results for Q3 2023, with total revenue of $35.1 million, a 72% increase YoY. U.S. handpiece and consumables revenue reached $17.0 million, up 113% YoY. Monthly account utilization increased by 5% compared to Q2 2023. The company sold 38 U.S. robotic systems, with robotic system and rental revenue of $13.5 million, up 37% YoY. Fiscal year 2023 total revenue guidance raised to $133.5 million. PROCEPT BioRobotics also completed an equity follow-on offering, raising $162 million in net proceeds, and received FDA IDE approval for Aquablation Therapy for Prostate Cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.37%
Tags
earnings
-
News
PROCEPT BioRobotics to Report Third Quarter 2023 Financial Results on November 1, 2023
Rhea-AI Summary
PROCEPT BioRobotics to report Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.71%
Tags
conferences earnings
-
News
The National Institute for Health and Care Excellence Endorses Aquablation® Therapy with "Standard Arrangements" Recommendation
Rhea-AI Summary
PROCEPT BioRobotics receives strong endorsement from NICE for Aquablation therapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.7%
Tags
none
News
PROCEPT BioRobotics Announces New Corporate Headquarters in San Jose
Rhea-AI Summary
PROCEPT BioRobotics announces grand opening of global corporate headquarters in San Jose
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
none
-
News
PROCEPT BioRobotics® Receives U.S. FDA Investigational Device Exemption to Investigate Aquablation® Therapy for Prostate Cancer
Rhea-AI Summary
PROCEPT BioRobotics receives FDA approval for IDE study on Aquablation therapy for prostate cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
none
-
News
PROCEPT BioRobotics® Announces First Commercial Aquablation Therapy Procedures in Japan
Rhea-AI Summary
PROCEPT BioRobotics completes first commercial Aquablation therapy procedures in Japan, marking an important milestone in global expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
none
News
PROCEPT BioRobotics to Present at the 2023 Wells Fargo Healthcare Conference in Boston
Rhea-AI Summary
PROCEPT BioRobotics® (Nasdaq: PRCT) will present at the 2023 Wells Fargo Healthcare Conference in Boston on September 7 at 3:00 p.m. Eastern Time. The presentation will be available via live webcast and archived on the company's website for at least 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
conferences
Stock PRCT logo
PROCEPT BioRobotics Corporation

Nasdaq:PRCT

PRCT Rankings

#1452 Ranked by Market Cap
#4434 Ranked by Stock Gains
N/A Ranked by Dividends

PRCT Stock Data

3.56B
43.88M
3.62%
91.61%
9.12%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
SAN JOSE

About PRCT

based in silicon valley, procept biorobotics is a privately held surgical robotics company enabling better patient care by developing transformative solutions in urology. with an initial focus on benign prostatic hyperplasia (bph), the company’s first product, the aquabeam system delivering aquablation therapy, is the world’s first commercially available minimally invasive surgical robot providing autonomous tissue removal to safely and effectively treat bph. aquablation therapy offers predictable and reproducible outcomes, independent of prostate anatomy or surgeon experience.